4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)isothiazole | 1611451-25-2

• 分子结构分类: 有机化合物
• 英文名称: 4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)isothiazole
• 英文别名: 4-[4-[[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy]-2-methylpyrimidin-5-yl]-1,2-thiazole
• CAS: 1611451-25-2
• 化学式: C₁₈H₁₈N₄O₂S
• 分子量: 354.433
• InChiKey: HEGIETKCBRPYSB-DOMZBBRYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  98.3
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014081619A1

  公开（公告）日：2014-05-30

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，这些化合物用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统障碍的治疗剂。本发明还涉及使用这些化合物来治疗神经和精神障碍，如精神分裂症、精神疾病或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
• PYRIMIDINE PDE10 INHIBITORS
  申请人：MCCOMAS Casey C.

  公开号：US20150307489A1

  公开（公告）日：2015-10-29

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，其可作为治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经和精神障碍，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• US9663513B2
  申请人：——

  公开号：US9663513B2

  公开（公告）日：2017-05-30